Cargando…

Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group

The International Staging System (ISS) and the Revised International Staging System (R-ISS) are commonly used prognostic scores in multiple myeloma (MM). These methods have significant gaps, particularly among intermediate-risk groups. The aim of this study was to improve risk stratification in newl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mosquera Orgueira, Adrian, González Pérez, Marta Sonia, Diaz Arias, Jose, Rosiñol, Laura, Oriol, Albert, Teruel, Ana Isabel, Martinez Lopez, Joaquin, Palomera, Luis, Granell, Miguel, Blanchard, Maria Jesus, de la Rubia, Javier, López de la Guia, Ana, Rios, Rafael, Sureda, Anna, Hernandez, Miguel Teodoro, Bengoechea, Enrique, Calasanz, María José, Gutierrez, Norma, Martin, Maria Luis, Blade, Joan, Lahuerta, Juan-Jose, San Miguel, Jesús, Mateos, Maria Victoria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038663/ https://www.ncbi.nlm.nih.gov/pubmed/35468898 http://dx.doi.org/10.1038/s41408-022-00647-z

Ejemplares similares

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma
por: Puig, Noemí, et al.
Publicado: (2022)

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials
por: Lopez-Anglada, Lucia, et al.
Publicado: (2018)

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
por: Rodríguez-Otero, Paula, et al.
Publicado: (2019)

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
por: Encinas, Cristina, et al.
Publicado: (2022)

Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic
por: Martínez-López, Joaquín, et al.
Publicado: (2021)

NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial
por: Rosa-Rosa, Juan Manuel, et al.
Publicado: (2022)

Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations()
por: Lopez, Aurelio, et al.
Publicado: (2015)

Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
por: Martínez-López, Joaquín, et al.
Publicado: (2020)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
por: Rosiñol, Laura, et al.
Publicado: (2023)

P848: EXPRESSION PROFILE OF BCL-2 FAMILY PROTEINS IN MULTIPLE MYELOMA.
por: Sánchez, Cristina De Ramón, et al.
Publicado: (2023)

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients
por: Medina, Alejandro, et al.
Publicado: (2020)

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial
por: Puig, Noemí, et al.
Publicado: (2020)

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
por: Puig, Noemi, et al.
Publicado: (2021)

Expression of p53 protein isoforms predicts survival in patients with multiple myeloma
por: Rojas, Elizabeta A., et al.
Publicado: (2022)

Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma
por: Puig, Noemí, et al.
Publicado: (2021)

Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project
por: Blade, Joan, et al.
Publicado: (2018)

P878: SELINEXOR IN COMBINATION WITH DARATUMUMAB-BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF RELAPSE OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF THE PHASE 2, MULTICENTER GEM-SELIBORDARA STUDY
por: Gonzalez-Calle, Veronica, et al.
Publicado: (2023)

A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility
por: Misiewicz-Krzeminska, Irena, et al.
Publicado: (2018)

Measurable residual disease in multiple myeloma: ready for clinical practice?
por: Burgos, Leire, et al.
Publicado: (2020)

Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
por: Puertas, Borja, et al.
Publicado: (2023)

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
por: Botta, Cirino, et al.
Publicado: (2023)

Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma
por: Leivas, Alejandra, et al.
Publicado: (2016)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020)

Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma
por: Alegre, Adrián, et al.
Publicado: (2020)

P967: A MACHINE LEARNING MODEL FOR RISK PREDICTION IN MULTIPLE MYELOMA PROGRESSING AFTER THE FIRST LINE OF THERAPY
por: Mosquera-Orgueira, Adrian, et al.
Publicado: (2023)

Prognostic Stratification of Multiple Myeloma Using Clinicogenomic Models: Validation and Performance Analysis of the IAC-50 Model
por: Mosquera Orgueira, Adrián, et al.
Publicado: (2022)

Recent Advances in the Treatment of Patients with Multiple Myeloma
por: Legarda, Mario A., et al.
Publicado: (2020)

Tumor Reduction in Multiple Myeloma: New Concepts for New Therapeutics
por: Alonso, Rafael, et al.
Publicado: (2022)

Deficient Spindle Assembly Checkpoint in Multiple Myeloma
por: Díaz-Rodríguez, Elena, et al.
Publicado: (2011)

The renal range of the κ/λ sFLC ratio: best strategy to evaluate multiple myeloma in patients with chronic kidney disease
por: Molina-Andújar, Alícia, et al.
Publicado: (2020)

Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution
por: Jiménez-Segura, Raquel, et al.
Publicado: (2022)

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
por: Moreau, Philippe, et al.
Publicado: (2023)

The DAC system and associations with multiple myeloma
por: Ocio, Enrique M., et al.
Publicado: (2010)

The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach
por: Ríos-Tamayo, Rafael, et al.
Publicado: (2021)

Biological Characterization and Clinical Relevance of Circulating Tumor Cells: Opening the Pandora’s Box of Multiple Myeloma
por: Garcés, Juan-José, et al.
Publicado: (2022)

CAR T-Cells in Multiple Myeloma Are Ready for Prime Time
por: Rodríguez-Otero, Paula, et al.
Publicado: (2020)

Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma
por: Martinez-Lopez, J, et al.
Publicado: (2017)

Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition
por: Granell, Miquel, et al.
Publicado: (2017)

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network
por: Moreau, Philippe, et al.
Publicado: (2019)

Deregulation of DNA Double-Strand Break Repair in Multiple Myeloma: Implications for Genome Stability
por: Herrero, Ana B., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_m7es7hso66knu412b7rl06e3eb